Type 2 diabetes

News

Lilly says oral GLP-1 could be 'foundational' diabetes drug

Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.

News

New NHS diabetes strategy could raise GLP-1 drug use

New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments.

News

ADA: Lilly makes its case for oral GLP-1 orforglipron

Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.

News

NICE changes its mind on Lilly's Mounjaro for diabetes

Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after the drug was recommended for NHS use by cost-effectiven

News

Jardiance is first SGLT2 given FDA OK for use in children

With rates of juvenile type 2 diabetes rocketing in the US, doctors now have access to an alternative oral therapy – the first new oral option for more than 20 years.

Market Access